Evidence map›Paper›PMID 16361132›Full record

ReviewCancer imaging : the official publication of the International Cancer Imaging Society2005

Translational molecular imaging for cancer.

Martin G Pomper

Abstract readReview
In one paragraph

Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Advances in prostate cancer research and treatment.BioMed research international · 2014
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Use of radionuclides in cancer research and treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2009
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Imaging virus-associated cancer.Current pharmaceutical design · 2008
    Review
  15. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application.Clinical cancer research : an official journal of the American Association for Cancer Research · 2006
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Martin G PomperThe Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD 21287-2182, USA. mpomper@jhmi.edu

Funding

NCI NIH HHS CA92871
6 · The paper itself

Abstract

Although most clinical diagnostic imaging studies employ anatomic techniques such as computed tomography (CT) and magnetic resonance (MR) imaging, much of radiology research currently focuses on adapting these conventional methods to physiologic imaging as well as on introducing new techniques and probes for studying processes at the cellular and molecular levels in vivo, i.e. molecular imaging. Molecular imaging promises to provide new methods for the early detection of cancer and support for personalized cancer therapy. Although molecular imaging has been practiced in various incarnations for over 20 years in the context of nuclear medicine, other imaging modalities have only recently been applied to the noninvasive assessment of physiology and molecular events. Nevertheless, there has been sufficient experience with specifically targeted contrast agents and high-resolution techniques for MR imaging and other modalities that we must begin moving these new technologies from the laboratory to the clinic. This brief review outlines several of the more promising areas of pursuit in molecular imaging for oncology with an emphasis on those that show the most immediate likelihood for clinical translation.

Indexed as

Technology TransferAnimalsBiochemical PhenomenaBiomarkers, TumorDiagnostic ImagingHumansMedical OncologyNeoplasmsRadiopharmaceuticalsBiomarkers, TumorRadiopharmaceuticals

Identifiers

PMID16361132
PMCPMC1665308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.